Long-term Extension Study of Anavex 2-73, Potential Treatment of Alzheimer’s Dementia, Opens

Long-term Extension Study of Anavex 2-73, Potential Treatment of Alzheimer’s Dementia, Opens
Anavex Life Sciences has launched an extension study — called ATTENTION-AD — to investigate the long-term safety and efficacy of Anavex 2-73 in delaying cognitive decline in people with early Alzheimer’s disease. Eligible patients are those now taking part in the company's 48-week ANAVEX2-73-AD-004 study underway in Australia. “This is an important development as the patients who have completed the main study … are consistently expressing the wish to gain ongoing access to this investigational therapy,” Stephen Macfarlane, head of clinical services at the Dementia Centre of HammondCare and principal investigator for both trials, said in a press release. Anavex 2-73 (blarcamesine) is an investigational oral disease-modifying therapy that binds to and activates a cell receptor called Sigma-1 that's known to have neuroprotective effects. Specifically, Anavex 2-73 is thought to help restore cellular balance by targeting protein misfolding (which prevents them from working as intended), oxidative stress ( oxygen molecules with free radicals, or unpaired electrons, that damage cells), mitochondrial dysfunction, inflammation, and cellular stress. Results from an earlier, open-label Phase 2a trial and its ongoing extension study (NCT02244541 and
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *